PDCD1 and neoplasm: STING agonists have also been shown to be well-suited for combination with immune checkpoint blockade, particularly anti-PD-1, to overcome resistance to PD-1 blockade as well as render poorly immunogenic tumours to become sensitive to immune checkpoint inhibitors51–58.